Used primarily in cancer research, Tenovin-3 activates the p53 pathway by inhibiting MDM2, a protein that degrades p53. This stabilization of p53 promotes apoptosis in tumor cells, making it a valuable tool for studying anticancer therapies. It has shown activity against various cancer cell lines in preclinical models, particularly those with wild-type p53. Additionally, Tenovin-3 exhibits antimetastatic properties and enhances the effects of other chemotherapeutic agents. Its use is largely confined to laboratory research due to limitations in solubility and bioavailability for clinical use.